VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have ...
Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms ...
The 2025 WHO-FIGO-ICM guidelines lower diagnostic thresholds and promote objective measurement to detect postpartum hemorrhage (PPH) earlier A bundled, simultaneous approach (e.g. E-MOTIVE) is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback